Established in Beverly MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 260 employees. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state antibodies utilized to expand knowledge of cell signaling pathways. Aberrant signaling within these pathways has been implicated in various diseases including cancer, diabetes and neurodegenerative diseases.

In addition to product development and production, CST is also actively engaged in research into new technology development as well as primary cell biology research. CST scientists publish their findings in the highest quality peer-reviewed journals including Nature Biotechnology, Cell, Journal of Immunology and Journal of Biological Chemistry. CST continues to expand our NIH-funded bioinformatics resource PhosphoSitePlus®. This website contains curated information about known and new protein modification sites in proteins from human, mouse and related species.